Since the approval of imatinib, patients now have over 80-85%
long-
term survival. However, not all patients respond to or are able to tolerate imatinib.
Fortunately, in the last several years, two other agents (these are referred to as second-generation tyrosine kinase inhibitors) – dasatinib (Sprycel®) and nilotinib (Tasigna©) have both been shown to be at least equally effective (and likely better) in treating CML.